Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
Chlorozotocin, 120 mg/m2 every 4 weeks, was administered to 22 patients with advanced soft tissue sarcoma. All patients had received extensive prior chemotherapy and had measurable progressive disease at the time of entry in the study. No objective responses were observed. The best individual results were in three patients with disease stabilization lasting 2--4 months. Toxic effects included nausea in one half of the patients and sweating episodes in one. One patient developed temporary leukopenia and three had thrombocytopenia that lasted for 3 weeks, 4 weeks, and 4 months. Blood sugar levels were unaffected by the treatment. No renal or hepatic toxicity was recorded.